companydata.dkNovo Nordisk Research Center Gladsaxe ApS: Financial statements 2023
CVR: 39119374
Novo Nordisk Research Center Gladsaxe ApS (CVR 39119374) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK 395,475,000 compared with DKK -8,830,214 the year before. Equity amounted to DKK 405,585,000. The solvency ratio was 78.5%. The company had 2 employees in the financial year.
- Profit/Loss
- 395,475,000 kr.
- Equity
- 405,585,000 kr.
- Total Assets
- 516,988,000 kr.
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | 395.5 mio. | 405.6 mio. | 2 |
| 2022 | - | 379 t. | -8.8 mio. | -5.9 mio. | 4 |
| 2021 | - | 0 | -6.2 mio. | 2.9 mio. | 3 |
| 2020 | - | 10.7 mio. | 3.2 mio. | 9.5 mio. | 5 |
| 2019 | - | 25.6 mio. | 14.4 mio. | 18.3 mio. | 5 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of August 29, 2023, Peter Bøggild has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Kristine Aachmann Bethe has joined the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Casper Tind Hansen has left the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Klaus Christian Schollmeier has left the board of directors of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Trine Haastrup is registered as director of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Casper Tind Hansen has stepped down as adm. dir. of Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, Jakob Bondo Hansen has stepped down as director of Novo Nordisk Research Center Gladsaxe ApS.
On August 29, 2023, the company changed its name from Embark Biotech ApS to Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, NOVO NORDISK A/S is registered as an owner of Novo Nordisk Research Center Gladsaxe ApS with an ownership share of 100%.
Novo Nordisk Research Center Gladsaxe ApS has published its annual report for 2022. Gross profit came to DKK 379,438, and the net result was DKK -8,830,214.
About Novo Nordisk Research Center Gladsaxe ApS
Novo Nordisk Research Center Gladsaxe ApS is a Danish company of the type Anpartsselskab based in Bagsværd, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Embark Biotech ApS and Embark Biotech IvS. The management consists of Rikke Ryttergaard Andersen. The company is owned by NOVO NORDISK A/S. The company has 7 employees. In 2025, the company reported a gross profit of DKK -1,000 and a net result of DKK 48,000 compared with DKK 6,174,000 the year before. Equity amounted to DKK 807,000.